Selvigaltin (GB1211), an orally accessible small molecule galectin-3 inhibitor developed being a treatment for liver fibrosis and cirrhosis, was evaluated to assess the influence of hepatic impairment on its pharmacokinetics and safety to address regulatory necessities. Participants were also excluded if that they had clinically sizeable abnormalities in electrocardiogram (ECG) https://troybghge.blog-mall.com/39943023/selvigaltin-gb1211-for-dummies